Latest news
Serodus ASA’s Board of Directors has in agreement with our CEO Eva Steiness decided to relieve her for the administrative burden to manage Serodus ASA from her permanent address in Denmark.
Serodus Board has appointed Mr. Arnstein Endresen, previous member of the Board of Directors and decided to place/outsource all SER150 management to the 100% Serodus ASA owned Danish subsidiary, Phlogo ApS.
Eva Steiness is CEO in Phlogo and will in this capacity continue to manage SER150 development for the treatment of patients with Diabetic Kidney Disease.
- Transition to the new Australian based CRO was finalized during Q3.
- Australian ethical committee has approved increasing dosing period from 3 to 6 months.
- Reactivation of Australian centers by the new CRO.
- Centers in New Zealand are being added to the Australian centers.
- Still low number of patients entered the study in Q2-2022.
- A new Australian based CRO for SER150 CL-009 clinical study will continue the study on Serodus behalf.
- Complete transfer expected to be finalized mid Q3-2022.
- Australian ethical committee has approved increasing dosing period from 3 to 6 months.
Download: Presentation AGM 2022
Download: Minutes from General Meeting
AGM 2022 to be postponed until late june 2022
SERODUS ASA – Publishes 2021 Annual Report
Highlights
- SER150 clinical study in Australia is still delayed after Covid19 lockdowns
- Serodus received Australian governmental refund (RDTI) for the SER150 Cl-009 study activities.
- The Group qualified for and received a “Patent Voucher” from the Ministry of Commerce in Denmark supporting the patent strategy of the subsidiary Phlogo ApS.
Go to the report: Serodus ASA QR 2022 – Q1